Overview

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Status:
RECRUITING
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study
Phase:
PHASE1
Details
Lead Sponsor:
Amneal Pharmaceuticals, LLC
Collaborators:
Amneal EU, Limited
CBCC Global Inc.
Treatments:
Bimatoprost